168 related articles for article (PubMed ID: 21890295)
1. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting.
Anzalone N; Scarabino T; Venturi C; Cristaudo C; Tartaro A; Scotti G; Zimatore D; Floris R; Carriero A; Longo M; Cirillo M; Cova MA; Gatti S; Voth M; Colosimo C
Eur J Radiol; 2013 Jan; 82(1):139-45. PubMed ID: 21890295
[TBL] [Abstract][Full Text] [Related]
2. Re: Cerebral neoplastic enhancing lesions: Multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting.
Desché P
Eur J Radiol; 2012 Oct; 81(10):e967; author reply 2925-6. PubMed ID: 22578838
[No Abstract] [Full Text] [Related]
3. Brain MRI with single-dose (0.1 mmol/kg) Gadobutrol at 1.5 T and 3 T: comparison with 0.15 mmol/kg Gadoterate meglumine.
Kramer H; Runge VM; Naul LG; Loynachan AT; Reiser MF; Wintersperger BJ
AJR Am J Roentgenol; 2010 May; 194(5):1337-42. PubMed ID: 20410423
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T.
Attenberger UI; Runge VM; Jackson CB; Baumann S; Birkemeier K; Michaely HJ; Schoenberg SO; Reiser MF; Wintersperger BJ
Invest Radiol; 2009 May; 44(5):251-6. PubMed ID: 19550376
[TBL] [Abstract][Full Text] [Related]
5. MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T.
Saake M; Langner S; Schwenke C; Weibart M; Jansen O; Hosten N; Doerfler A
Eur Radiol; 2016 Mar; 26(3):820-8. PubMed ID: 26123410
[TBL] [Abstract][Full Text] [Related]
6. Less is better? Intraindividual and interindividual comparison between 0.075 mmol/kg of gadobenate dimeglumine and 0.1 mmol/kg of gadoterate meglumine for cranial MRI.
Khouri Chalouhi K; Papini GDE; Bandirali M; Sconfienza LM; Di Leo G; Sardanelli F
Eur J Radiol; 2014 Jul; 83(7):1245-1249. PubMed ID: 24816087
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T.
Attenberger UI; Runge VM; Morelli JN; Williams J; Jackson CB; Michaely HJ
J Magn Reson Imaging; 2010 Mar; 31(3):549-55. PubMed ID: 20187196
[TBL] [Abstract][Full Text] [Related]
8. Dynamic and static magnetic resonance angiography of the supra-aortic vessels at 3.0 T: intraindividual comparison of gadobutrol, gadobenate dimeglumine, and gadoterate meglumine at equimolar dose.
Kramer JH; Arnoldi E; François CJ; Wentland AL; Nikolaou K; Wintersperger BJ; Grist TM
Invest Radiol; 2013 Mar; 48(3):121-8. PubMed ID: 23211552
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
[TBL] [Abstract][Full Text] [Related]
10. MR Angiography at 3 T of Peripheral Arterial Disease: A Randomized Prospective Comparison of Gadoterate Meglumine and Gadobutrol.
Loewe C; Arnaiz J; Krause D; Marti-Bonmati L; Haneder S; Kramer U;
AJR Am J Roentgenol; 2015 Jun; 204(6):1311-21. PubMed ID: 26001243
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 0.5 M gadoterate and 1.0 M gadobutrol in peripheral MRA: a prospective, single-center, randomized, crossover, double-blind study.
Haneder S; Attenberger UI; Schoenberg SO; Loewe C; Arnaiz J; Michaely HJ
J Magn Reson Imaging; 2012 Nov; 36(5):1213-21. PubMed ID: 22848033
[TBL] [Abstract][Full Text] [Related]
12. The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study).
Vaneckova M; Herman M; Smith MP; Mechl M; Maravilla KR; Weichet J; Spampinato MV; Žižka J; Wippold FJ; Baima JJ; Babbel R; Bültmann E; Huang RY; Buhk JH; Bonafé A; Colosimo C; Lui S; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJNR Am J Neuroradiol; 2015 Sep; 36(9):1589-98. PubMed ID: 26185325
[TBL] [Abstract][Full Text] [Related]
13. Intraindividual, randomized comparison of the macrocyclic contrast agents gadobutrol and gadoterate meglumine in breast magnetic resonance imaging.
Fallenberg EM; Renz DM; Karle B; Schwenke C; Ingod-Heppner B; Reles A; Engelken FJ; Huppertz A; Hamm B; Taupitz M
Eur Radiol; 2015 Mar; 25(3):837-49. PubMed ID: 25249313
[TBL] [Abstract][Full Text] [Related]
14. Gadobutrol in the central nervous system at three doses: results from a phase II, randomized, multicenter trial.
Breuer J; Gutierrez J; Latchaw R; Lehr R; Sorensen AG
J Magn Reson Imaging; 2014 Feb; 39(2):410-8. PubMed ID: 23681501
[TBL] [Abstract][Full Text] [Related]
15. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).
Seidl Z; Vymazal J; Mechl M; Goyal M; Herman M; Colosimo C; Pasowicz M; Yeung R; Paraniak-Gieszczyk B; Yemen B; Anzalone N; Citterio A; Schneider G; Bastianello S; Ruscalleda J
AJNR Am J Neuroradiol; 2012 Jun; 33(6):1050-8. PubMed ID: 22383237
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance evaluation of renal artery stenosis in a swine model: performance of low-dose gadobutrol versus gadoterate meglumine in comparison with digital subtraction intra-arterial catheter angiography.
Morelli JN; Runge VM; Ai F; Zhang W; Li X; Schmitt P; McNeal G; Miller M; Lennox M; Wusten O; Schoenberg SO; Attenberger UI
Invest Radiol; 2012 Jun; 47(6):376-82. PubMed ID: 22543971
[TBL] [Abstract][Full Text] [Related]
17. Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system.
Gutierrez JE; Rosenberg M; Duhaney M; Simon JA; Brueggenwerth G; Agris JM; Knopp EA
J Magn Reson Imaging; 2015 Mar; 41(3):788-96. PubMed ID: 24578298
[TBL] [Abstract][Full Text] [Related]
18. A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours.
Colosimo C; Knopp MV; Barreau X; Gérardin E; Kirchin MA; Guézénoc F; Lodemann KP
Neuroradiology; 2004 Aug; 46(8):655-65. PubMed ID: 15205859
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention.
Kuhn MJ; Picozzi P; Maldjian JA; Schmalfuss IM; Maravilla KR; Bowen BC; Wippold FJ; Runge VM; Knopp MV; Wolansky LJ; Gustafsson L; Essig M; Anzalone N
J Neurosurg; 2007 Apr; 106(4):557-66. PubMed ID: 17432704
[TBL] [Abstract][Full Text] [Related]
20. CAIPIRINHA-Dixon-TWIST (CDT)-volume-interpolated breath-hold examination (VIBE) for dynamic liver imaging: comparison of gadoterate meglumine, gadobutrol and gadoxetic acid.
Budjan J; Ong M; Riffel P; Morelli JN; Michaely HJ; Schoenberg SO; Haneder S
Eur J Radiol; 2014 Nov; 83(11):2007-12. PubMed ID: 25172427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
